中国临床药学杂志2024，Vol.33Issue(2)：117-124,8.DOI:10.19577/j.1007-4406.2024.02.007
哌拉西林他唑巴坦联合喹诺酮类药物治疗非重症下呼吸道感染的有效性和安全性的Meta分析
Meta-analysis of the efficacy and safety of piperacillin-tazobactam plus fluoroquinolones in the treatment of non-critical patients with lower respiratory tract infections
摘要
Abstract
AIM To systematically review the validity and safety of piperacillin-tazobactam plus fluoroquinolones in the therapy of non-critical patients with lower respiratory tract infections.METHODS The foreign databases including the Cochrane Library,PubMed,Embase,Web of Science,and Chinese databases including CNKI,WanFang,VIP,and CBM were searched to collect randomized controlled trials(RCTs)involving the comparison of piperacillin-tazobactam monotherapy with piperacillin-tazobactam plus fluoroquinolones for the treatment of non-critical patients with lower respiratory tract infections up to April 2023.The Meta-analysis and sensitivity analysis were conducted using the RevMan 5.4 and Stata 18.0 software respectively.RESULTS 14 RCTs involving 1116 patients were included.The Meta-analysis results indicated that the fluoroquinolones plus piperacillin-tazobactam could improve treatment efficacy[OR=4.77,95％CI(3.04-7.49),Z=6.79,P＜0.000 01],shorten cough relief time[OR=-2.08,95％CI(-3.43--0.72),Z=3.01,P=0.003],shorten body temperature recovery time[OR=-2.14,95％CI(-2.83--1.45),Z=6.05,P＜0.000 01],shorten lesions absorption time[OR=-2.28,95％CI(-3.50--1.06),Z=3.66,P=0.000 3],effectively lower C-reactive protein(CRP)level[OR=6.48,95％CI(0.59-12.36),Z=2.16,P=0.03],and improve bacterial clearance rate[OR=4.51,95％CI(2.00-10.16),Z=3.64,P=0.000 3]compared to piperacillin-tazobactam monotherapy.There was no significant difference in the decrease in levels of white blood cell and adverse drug reactions between 2 groups(P＞0.05).CONCLUSION Piperacillin-tazobactam plus fluoroquinolones could improve clinical efficacy,alleviate symptoms,and show good safety in the treatment of non-critical patients with lower respiratory tract infections.However,due to the difference in methodological quality,a small sample size,and more high-quality and large-sample RCTs evidence support is still needed.关键词
哌拉西林他唑巴坦/Meta分析/喹诺酮类药物/下呼吸道感染Key words
piperacillin-tazobactam/Meta-analysis/fluoroquinolones/lower respiratory tract infection引用本文复制引用
杨强,唐平秀,张询研,张鹏..哌拉西林他唑巴坦联合喹诺酮类药物治疗非重症下呼吸道感染的有效性和安全性的Meta分析[J].中国临床药学杂志,2024,33(2):117-124,8.基金项目
四川省中医药管理局科学技术研究专项课题(编号2020CP0027) （编号2020CP0027）
